Myocardial ischemia–related pathways

Myocardial ischemia–related pathways encompass the complex molecular and cellular responses triggered by a deficiency in blood and oxygen supply to the heart muscle. These pathways involve a rapid shift from oxidative phosphorylation to anaerobic glycolysis, resulting in ATP depletion, intracellular acidosis, and the accumulation of reactive oxygen species (StatPearls, 2023). Key regulatory elements include Hypoxia-Inducible Factor 1-alpha (HIF-1α), which coordinates the expression of genes involved in angiogenesis and glucose metabolism, and various mitogen-activated protein kinase (MAPK) cascades that regulate cell survival and apoptosis (PubMed, PMC4315672). In clinical practice, these pathways are the focus of treatments aimed at restoring coronary flow and reducing myocardial oxygen consumption to prevent tissue necrosis and subsequent heart failure (NIH, 2022). Because this term describes a broad set of physiological events and signaling networks rather than a single protein, enzyme, or receptor, it is classified as a pathway group rather than a discrete therapeutic target.

Other names

Ischemic heart disease pathwaysMyocardial ischemia-reperfusion injury pathwaysCoronary artery disease pathwaysCardiac ischemia signaling

Pharmacological agents targeting these pathways act by increasing myocardial oxygen supply through coronary vasodilation, decreasing myocardial oxygen demand by reducing heart rate and contractility, inhibiting thrombus formation via antiplatelet and anticoagulant effects, and stabilizing atherosclerotic plaques.